18.92
-0.39
(-2.02%)
After Hours: 19.10
+0.18
(0.95%)
Jun 17, 5:57PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 18.75 - 19.71 |
| 52 week | 1.42 - 20.09 |
| Open | 19.49 |
| Vol / Avg. | 3.15M/3.73M |
| Mkt cap | 1.50B |
| P/E | - |
| Div/yield | - |
| EPS | -0.34 |
| Shares | 79.16M |
| Beta | 2.88 |
| Inst. own | 75% |
Events
Aug 5, 2013
Q2 2013 ACADIA Pharmaceuticals Earnings Release
Jun 7, 2013
ACADIA Pharmaceuticals Annual Shareholder Meeting
Jun 5, 2013
ACADIA Pharmaceuticals at Jefferies Global Healthcare Conference -
May 23, 2013
ACADIA Pharmaceuticals at BioCentury Publications BioEquity Europe Conference
May 8, 2013
Q1 2013 ACADIA Pharmaceuticals Earnings Release
May 7, 2013
Q1 2013 ACADIA Pharmaceuticals Earnings Conference Call -
Apr 30, 2013
ACADIA Pharmaceuticals at Needham Healthcare Conference -
Apr 11, 2013
ACADIA Pharmaceuticals Conference Call to Discuss Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -1468.35% | -424.88% |
| Operating margin | -1478.18% | -425.64% |
| EBITD margin | - | -423.42% |
| Return on average assets | -23.21% | -29.64% |
| Return on average equity | -29.83% | -38.49% |
| Employees | 26 | - |
| Carbon Disclosure Rating | - | - |
Address
3911 Sorrento Valley Blvd
SAN DIEGO, CA 92121
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)
SAN DIEGO, CA 92121
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Officers and directors
| Leslie L. Iversen Ph.D. | Independent Chairman of the Board | |
| Uli Hacksell Ph.D. | President, Chief Executive Officer, Director | |
| Thomas H. Aasen | Chief Financial Officer, Chief Business Officer, Executive Vice President, Treasurer | |
| Roger M. Mills M.D. | Executive Vice President - Development, Chief Medical Officer | |
| Glenn F. Baity | Vice President, General Counsel, Secretary | |
| Stephen R. Biggar M.D., Ph.D. | Independent Director | |
| Michael T. Borer | Independent Director | |
| Laura A. Brege | Independent Director | |
| Mary A. Gray Ph.D. | Independent Director | |
| Lester J. Kaplan Ph.D. | Independent Director |
